739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Renaud Sabatier ,E.M Guerra-Alia,Coline Montégut ,Nicoletta Colombo ,Claire Cropet ,Alain Gratet ,Laure Favier ,Frederik Marmé ,Rémy Largillier ,Sakari Hietanen ,F Rousseau ,Saverio Cinieri ,Éric Pujade-Lauraine ,Ulrich Canzler ,J Frindte ,Hiroyuki Yoshida ,Florence Joly ,Gerhard Bogner ,Ignace Vergote ,Isabelle Ray‐Coquard

doi:10.1016/j.annonc.2021.08.1181

739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Renaud Sabatier , E.M Guerra-Alia + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1181

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Hospital Universitario Ramón y Cajal, Spanish Ovarian Cancer Research Group

#Maintenance Olaparib #Advanced Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The randomized phase III PAOLA-1 study (NCT02477644) showed that addition of olaparib to bev maintenance improved progression-free survival (PFS) in pts with advanced OC (Ray-Coquard et al. NEJM 2019). We evaluated maintenance olaparib plus bev in the older subgroup of PAOLA-1 pts.

Full Text